Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer.
The aim of this study was to evaluate the survival outcomes and toxicity of postoperative chemoradiotherapy with capecitabine and concurrent intensity-modulated radiotherapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) in patients with stage II and III rectal cancer.We recruited 184 p...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4411062?pdf=render |
| _version_ | 1818525198418182144 |
|---|---|
| author | Ning-Ning Lu Jing Jin Shu-Lian Wang Wei-Hu Wang Yong-Wen Song Yue-Ping Liu Hua Ren Hui Fang Xin-Fan Liu Zi-Hao Yu Ye-Xiong Li |
| author_facet | Ning-Ning Lu Jing Jin Shu-Lian Wang Wei-Hu Wang Yong-Wen Song Yue-Ping Liu Hua Ren Hui Fang Xin-Fan Liu Zi-Hao Yu Ye-Xiong Li |
| author_sort | Ning-Ning Lu |
| collection | DOAJ |
| description | The aim of this study was to evaluate the survival outcomes and toxicity of postoperative chemoradiotherapy with capecitabine and concurrent intensity-modulated radiotherapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) in patients with stage II and III rectal cancer.We recruited 184 patients with pathologically proven, stage II or III rectal cancer. Following total mesorectal excision (TME), the patients were treated with capecitabine and concurrent IMRT/3D-CRT. The treatment regimen consisted of two cycles of oral capecitabine (1600 mg/m2/day), administered twice daily from day 1-14 of radiotherapy, followed by a 7-day rest. The median pelvic dose was 50 Gy in 25 fractions. Oxaliplatin-based adjuvant chemotherapy was administered after the chemoradiotherapy.The 5-year overall survival, disease-free survival and locoregional control (LRC) rates were 85.1%, 80% and 95.4%, respectively. Grade 3 and 4 toxicities were observed in 28.3% of patients during treatment. Grade 3 or 4 late toxicity, including neurotoxicity or gastrointestinal toxicity, was only observed in nine patients (4.9%).This study demonstrated that capecitabine chemotherapy with concurrent IMRT/3D-CRT following TME is safe, is well tolerated and achieves superior LRC and favorable survival rates, with acceptable toxicity. |
| first_indexed | 2024-12-11T06:06:24Z |
| format | Article |
| id | doaj.art-a38584e1bb874189b6bafeb2948dcad3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T06:06:24Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a38584e1bb874189b6bafeb2948dcad32022-12-22T01:18:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012460110.1371/journal.pone.0124601Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer.Ning-Ning LuJing JinShu-Lian WangWei-Hu WangYong-Wen SongYue-Ping LiuHua RenHui FangXin-Fan LiuZi-Hao YuYe-Xiong LiThe aim of this study was to evaluate the survival outcomes and toxicity of postoperative chemoradiotherapy with capecitabine and concurrent intensity-modulated radiotherapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) in patients with stage II and III rectal cancer.We recruited 184 patients with pathologically proven, stage II or III rectal cancer. Following total mesorectal excision (TME), the patients were treated with capecitabine and concurrent IMRT/3D-CRT. The treatment regimen consisted of two cycles of oral capecitabine (1600 mg/m2/day), administered twice daily from day 1-14 of radiotherapy, followed by a 7-day rest. The median pelvic dose was 50 Gy in 25 fractions. Oxaliplatin-based adjuvant chemotherapy was administered after the chemoradiotherapy.The 5-year overall survival, disease-free survival and locoregional control (LRC) rates were 85.1%, 80% and 95.4%, respectively. Grade 3 and 4 toxicities were observed in 28.3% of patients during treatment. Grade 3 or 4 late toxicity, including neurotoxicity or gastrointestinal toxicity, was only observed in nine patients (4.9%).This study demonstrated that capecitabine chemotherapy with concurrent IMRT/3D-CRT following TME is safe, is well tolerated and achieves superior LRC and favorable survival rates, with acceptable toxicity.http://europepmc.org/articles/PMC4411062?pdf=render |
| spellingShingle | Ning-Ning Lu Jing Jin Shu-Lian Wang Wei-Hu Wang Yong-Wen Song Yue-Ping Liu Hua Ren Hui Fang Xin-Fan Liu Zi-Hao Yu Ye-Xiong Li Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. PLoS ONE |
| title | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. |
| title_full | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. |
| title_fullStr | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. |
| title_full_unstemmed | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. |
| title_short | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. |
| title_sort | postoperative capecitabine with concurrent intensity modulated radiotherapy or three dimensional conformal radiotherapy for patients with stage ii and iii rectal cancer |
| url | http://europepmc.org/articles/PMC4411062?pdf=render |
| work_keys_str_mv | AT ningninglu postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT jingjin postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT shulianwang postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT weihuwang postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT yongwensong postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT yuepingliu postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT huaren postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT huifang postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT xinfanliu postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT zihaoyu postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer AT yexiongli postoperativecapecitabinewithconcurrentintensitymodulatedradiotherapyorthreedimensionalconformalradiotherapyforpatientswithstageiiandiiirectalcancer |